Mangrove Partners’s AbbVie ABBV Stock Holding History

Mangrove Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,027	Closed	-$932K	–	372
2025 Q3	$932K	Buy	+4,027	New	+$820K	0.07%	105
2024 Q4	–	Sell	-4,772	Closed	-$942K	–	155
2024 Q3	$942K	Buy	+4,772	New	+$891K	0.08%	105

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Mangrove Partners's ABBV Position: Q4 2025 in Review

Mangrove Partners sold out of AbbVie (ABBV) in Q4 2025, closing a stake of 4,027 shares — an estimated $932K sold.

Mangrove Partners first reported a position in ABBV in Q3 2024 and held it in 2 quarters. The position peaked at $942K in Q3 2024. 4,145 funds tracked by Wall St. Rank hold ABBV as of Q4 2025.

Mangrove Partners reported no remaining AbbVie position as of Q4 2025 after selling out during the quarter.
Mangrove Partners sold 4,027 AbbVie shares in Q4 2025, an estimated $932K.
Mangrove Partners first reported a position in AbbVie in Q3 2024 and held it in 2 quarters.
Mangrove Partners's AbbVie position peaked at $942K in Q3 2024.
4,145 funds tracked by Wall St. Rank held AbbVie as of Q4 2025.

Based on Mangrove Partners's 13F filing for Q4 2025, filed 17 Feb 2026.